<DOC>
	<DOCNO>NCT01270074</DOCNO>
	<brief_summary>The general aim project conduct randomize , double-blind , placebo-controlled clinical trial azithromycin determine whether treatment infancy safe prevent onset bronchiectasis . One hundred thirty infant recruit CF clinic Australia New Zealand treat 3 month three year age . The primary outcome proportion radiologically-defined bronchiectasis 3 year age . Safety mechanistic evaluation also undertake .</brief_summary>
	<brief_title>Prevention Bronchiectasis Infants With Cystic Fibrosis</brief_title>
	<detailed_description>SYNOPSIS OF PROTOCOL Title Multi-centre randomize placebo-controlled study azithromycin primary prevention radiologically-defined bronchiectasis infant Cystic Fibrosis Clinical Phase Phase 3 Protocol Number : AZI001 TGA Reference Number : Protocol Co-Chairs : Peter D. Sly &amp; Stephen M. Stick Microbiology Consultant : Lisa Saiman CT Consultant : Harm Tiddens Statistical Consultant : Nicholas deKlerk Study Design Randomized , double-blind parallel group . Participants randomize one follow 2 group 1:1 ratio 65 participant per group ; Group A : 10 mg/kg ( 200mg/5ml ) azithromycin three time weekly three year add standard CF therapy . Group B : match placebo three time weekly three year add standard CF therapy . Accrual Objective 130 child Accrual Period 24 month Study Duration 36 month Countries : Australia New Zealand Sites : Brisbane Au , Sydney , Au , Melbourne Au , Adelaide Au , Perth Au , Auckland Nz , Christchurch Nz . Primary Endpoint The primary endpoint proportion child radiologically-defined bronchiectasis age 3 year . Secondary Endpoints - The extent severity bronchiectasis age 3 year - The volume trap gas age 3 year - CF-related quality life - Time first pulmonary exacerbation - Proportion participant experience pulmonary exacerbation - Number course inhale oral antibiotic - Number day inhale antibiotic - Incidence hospitalizations/Accident Emergency department ( A &amp; E ) visit acute respiratory exacerbation - Number day hospitalize acute respiratory exacerbation - Number day intravenous antibiotic - Body mass index 3 year age . Exploratory Endpoints - Markers neutrophilic inflammation - Markers oxidative stress - Composition airway flora Safety Endpoints - Proportion participant grow P. aeruginosa BAL - Age acquisition P. aeruginosa BAL - Emergence macrolide-resistant S. aureus , small colony variant S. aureus non-tuberculous mycobacteria ( NTM ) - Treatment-related adverse event - Haematology clinical chemistry Inclusion Criteria Participants meet follow criterion eligible enrolment study participant : 1 . Children either sex diagnosis CF follow detection via New Born Screening ( NBS ) cystic fibrosis 2 . Participants , opinion Investigator , able comply protocol duration 3 . Written inform consent sign dated parent/legal guardian accord local regulation Exclusion Criteria Participants meet criterion eligible enrolment trial participant : 1 . Born &lt; 30 week gestation 2 . Prolonged mechanical ventilation first 3 month life 3 . Participation another randomize control trial within 3 month precede inclusion study 4 . A significant medical disease condition CF likely interfere child 's ability complete entire protocol 5 . Previous major surgery except meconium ileus 6 . Macrolide hypersensitivity Treatment Description ZITHROMAXÂ® ( azithromycin ) Study Procedures The study participant stratify investigational site randomly assign either azithromycin placebo three year . Statistical Considerations Participants randomize block treatment group placebo group use one-to-one ratio . Randomization stratify study site . This ensure approximately equal allocation group within site . Interim Analyses Interim analysis occur first 50 % child ( n=33 per group complete 12 month CT subject complete 12 month CT. Interim analyse determine safety success ( unethical continue ) . Stopping Rules Study enrolment may stop follow event occur : - Death participant relate study treatment . - The trial meet definition futility success either plan interim analysis</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<criteria>1 . Children either sex diagnosis CF follow detection via New Born Screening ( NBS ) cystic fibrosis 2 . Participants , opinion Investigator , able comply protocol duration 3 . Written inform consent sign dated parent/legal guardian accord local regulation 1 . Born &lt; 30 week gestation 2 . Prolonged mechanical ventilation first 3 month life 3 . Participation another randomize control trial within 3 month precede inclusion study 4 . A significant medical disease condition CF likely interfere child 's ability complete entire protocol 5 . Previous major surgery except meconium ileus 6 . Macrolide hypersensitivity</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>double blind placebo control randomised clinical trial</keyword>
	<keyword>azithromycin</keyword>
	<keyword>infant</keyword>
	<keyword>pediatric</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>bronchiectasis</keyword>
</DOC>